Silexion Therapeutics CORP Schedule 13G passive stakes

Reporting Persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed beneficial ownership of 0% of Silexion Therapeutics Corp's ordinary shares as of June 30, 2026.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.4% beneficial ownership stake in Silexion Therapeutics Corp.

Lind Global Fund III LP and affiliates reported a 6.4% beneficial ownership stake in Silexion Therapeutics Corp, primarily through warrants.

Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have disclosed a 9.9% beneficial ownership stake in Silexion Therapeutics Corp.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% passive beneficial ownership in Silexion Therapeutics Corp. ordinary shares.

Orca Capital AG has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Silexion Therapeutics Corp, holding 109,432 ordinary shares.

Orca Capital AG has reported a 6.2% beneficial ownership stake in Silexion Therapeutics Corp, holding 131,250 ordinary shares.

Lincoln Alternative Strategies LLC has reported a 6.18% beneficial ownership stake in Silexion Therapeutics Corp., holding 131,250 ordinary shares.

The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have reported a 2.4% beneficial ownership stake in Silexion Therapeutics Corp. as of March 31, 2025.

CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.9% in Silexion Therapeutics Corp. ordinary shares.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 6.6% in Silexion Therapeutics Corp., holding 112,242 ordinary shares as of December 31, 2024.

CVI Investments and Heights Capital Management jointly report beneficial ownership of 8.5% of Silexion Therapeutics' ordinary shares as of January 15, 2025.

A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a 4.99% beneficial ownership stake in Silexion Therapeutics Corp. ordinary shares following a recent Securities Purchase Agreement.